Home The Word Brain	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	The Word Brain 2015 – Free PDF | Print | Web A short guide to fast language learning	Free Abstracts

Multiple Sclerosis

Free Subscription Articles published in Arch Neurol Retrieve available abstracts of 58 articles: HTML format Text format

Single Articles

December 2012
1. SCHIRMER L , Rothhammer V, Hemmer B, Korn T, et al
   Enriched CD161high CCR6+ gammadelta T Cells in the Cerebrospinal Fluid of Patients With Multiple Sclerosis.
   Arch Neurol. 2012 Dec 17:1-7. doi: 10.1001/2013.
   PubMed     Text format     Abstract available
   
   
   
2. ALTAY EE , Fisher E, Jones SE, Hara-Cleaver C, et al
   Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic.
   Arch Neurol. 2012 Dec 17:1-7. doi: 10.1001/2013.
   PubMed     Text format     Abstract available
   
   
   November 2012
3. GREENBERG BM , Balcer L, Calabresi PA, Cree B, et al
   Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis.
   Arch Neurol. 2012 Nov 5:1-4. doi: 10.1001/jamaneurol.2013.1017.
   PubMed     Text format     Abstract available
   
   
   
4. QIAN P , Lancia S, Alvarez E, Klawiter EC, et al
   Association of neuromyelitis optica with severe and intractable pain.
   Arch Neurol. 2012;69:1482-7.
   PubMed     Text format     Abstract available
   
   
   October 2012
5. SAIDHA S , Sotirchos ES, Oh J, Syc SB, et al
   Relationships Between Retinal Axonal and Neuronal Measures and Global Central Nervous System Pathology in Multiple Sclerosis.
   Arch Neurol. 2012 Oct 1:1-10. doi: 10.1001/archneurol.2013.
   PubMed     Text format     Abstract available
   
   
   
6. GREEN AJ
   Getting Beyond the Ganglion Cell: Morphometric Adjustments for Retinal Optical Coherence Tomography in Multiple Sclerosis.
   Arch Neurol. 2012 Oct 1:1-3. doi: 10.1001/archneurol.2013.
   PubMed     Text format    
   
   
   
7. MARDER E , Gupta P, Ragland M, Stuve O, et al
   Cerebral and cervical venous outflow abnormalities are dynamic.
   Arch Neurol. 2012;69:1380-1.
   PubMed     Text format    
   
   
   September 2012
8. ARELLANO B , Hussain R, Zacharias T, Yoon J, et al
   Human Aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with Neuromyelitis Optica.
   Arch Neurol. 2012;69:1125-31.
   PubMed     Text format     Abstract available
   
   
   
9. MEALY MA , Wingerchuk DM, Greenberg BM, Levy M, et al
   Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.
   Arch Neurol. 2012;69:1176-80.
   PubMed     Text format     Abstract available
   
   
   August 2012
10. GOVINDARAJAN R , Salgado E
    Is it too early to predict the failure of natalizumab in NMO?
    Arch Neurol. 2012;69:1085.
    PubMed     Text format    
    
    
    
11. KIM SM , Go MJ, Sung JJ, Park KS, et al
    Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics.
    Arch Neurol. 2012;69:1026-31.
    PubMed     Text format     Abstract available
    
    
    July 2012
12. FENG X , Han D, Kilaru BK, Franek BS, et al
    Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins.
    Arch Neurol. 2012 Jul 16:1-7. doi: 10.1001/archneurol.2012.
    PubMed     Text format     Abstract available
    
    
    
13. RADUE EW , O'Connor P, Polman CH, Hohlfeld R, et al
    Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisImpact of Fingolimod Therapy in Multiple Sclerosis.
    Arch Neurol. 2012 Jul 2:1-11. doi: 10.1001/archneurol.2012.1051.
    PubMed     Text format     Abstract available
    
    
    
14. KORTH C
    Identification of Dominant Human Aquaporin 4 T-Cell Epitopes: Observations in Neuromyelitis Optica With Implications for Other Autoimmune DisordershAQP4 T-Cell Epitopes.
    Arch Neurol. 2012 Jul 2:1-2. doi: 10.1001/archneurol.2012.1561.
    PubMed     Text format    
    
    
    
15. REEKERS JA
    IDEAL for CCSVI research.
    Arch Neurol. 2012;69:939-40.
    PubMed     Text format    
    
    
    
16. BICHUETTI DB , Oliveira EM, Boulos Fde C, Gabbai AA, et al
    Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients.
    Arch Neurol. 2012;69:938-9.
    PubMed     Text format    
    
    
    June 2012
17. MARCUS JF , Goodin DS, Harris CA, Josephson SA, et al
    Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply.
    Arch Neurol. 2012;69:793-4.
    PubMed     Text format    
    
    
    
18. HANWELL HE , Kimball SM
    Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring.
    Arch Neurol. 2012;69:793-4.
    PubMed     Text format    
    
    
    April 2012
19. TORKILDSEN O , Wergeland S, Bakke S, Beiske AG, et al
    omega-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study): A Randomized, Double-Blind, Placebo-Controlled Trial.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
20. RENARD D , Poalelungi A, Collombier L, Labauge P, et al
    Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
    Arch Neurol. 2012;69:541-2.
    PubMed     Text format    
    
    
    March 2012
21. BOURRE B , Zephir H, Ongagna JC, Cordonnier C, et al
    Long-term follow-up of acute partial transverse myelitis.
    Arch Neurol. 2012;69:357-62.
    PubMed     Text format     Abstract available
    
    
    
22. MEALY MA , Newsome S, Greenberg BM, Wingerchuk D, et al
    Low serum vitamin D levels and recurrent inflammatory spinal cord disease.
    Arch Neurol. 2012;69:352-6.
    PubMed     Text format     Abstract available
    
    
    February 2012
23. SINNECKER T , Mittelstaedt P, Dorr J, Pfueller CF, et al
    Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage: A Comparative Ultrahigh-Field Strength Magnetic Resonance Imaging Study.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
24. VILLAR LM , Garcia-Sanchez MI, Costa-Frossard L, Espino M, et al
    Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Arch Neurol. 2012;69:191-7.
    PubMed     Text format     Abstract available
    
    
    
25. HAVLA JB , Pellkofer HL, Meinl I, Gerdes LA, et al
    Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Arch Neurol. 2012;69:262-4.
    PubMed     Text format     Abstract available
    
    
    
26. KLEITER I , Hellwig K, Berthele A, Kumpfel T, et al
    Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Arch Neurol. 2012;69:239-45.
    PubMed     Text format     Abstract available
    
    
    January 2012
27. POOL V , Gordon DM, Decker M
    Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow Fever vaccination.
    Arch Neurol. 2012;69:144.
    PubMed     Text format    
    
    
    
28. MARCUS JF , Shalev SM, Harris CA, Goodin DS, et al
    Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution.
    Arch Neurol. 2012;69:129-32.
    PubMed     Text format     Abstract available
    
    
    
29. CARAMANOS Z , Francis SJ, Narayanan S, Lapierre Y, et al
    Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis.
    Arch Neurol. 2012;69:89-95.
    PubMed     Text format     Abstract available
    
    
    
30. CHERIYAN J , Kim S, Wolansky LJ, Cook SD, et al
    Impact of inflammation on brain volume in multiple sclerosis.
    Arch Neurol. 2012;69:82-8.
    PubMed     Text format     Abstract available
    
    
    
31. GORMAN MP , Tillema JM, Ciliax AM, Guttmann CR, et al
    Daclizumab use in patients with pediatric multiple sclerosis.
    Arch Neurol. 2012;69:78-81.
    PubMed     Text format     Abstract available
    
    
    
32. USMANI N , Bedi G, Lam BL, Sheremata WA, et al
    Association between paroxysmal tonic spasms and neuromyelitis optica.
    Arch Neurol. 2012;69:121-4.
    PubMed     Text format     Abstract available
    
    
    December 2011
33. ZHANG B , Tzartos JS, Belimezi M, Ragheb S, et al
    Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
34. FILIPPI M , Rocca MA, De Stefano N, Enzinger C, et al
    Magnetic resonance techniques in multiple sclerosis: the present and the future.
    Arch Neurol. 2011;68:1514-20.
    PubMed     Text format     Abstract available
    
    
    
35. WILLIAMS MA , Venkatesan A
    No endovascular innovation without evaluation in chronic cerebrospinal venous insufficiency: a call for the IDEAL model.
    Arch Neurol. 2011;68:1510-2.
    PubMed     Text format    
    
    
    November 2011
36. TUR C , Montalban X, Tintore M, Nos C, et al
    Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up.
    Arch Neurol. 2011;68:1421-7.
    PubMed     Text format     Abstract available
    
    
    
37. CHAN KH , Tse CT, Chung CP, Lee RL, et al
    Brain involvement in neuromyelitis optica spectrum disorders.
    Arch Neurol. 2011;68:1432-9.
    PubMed     Text format     Abstract available
    
    
    
38. SAURE C , Warnke C, Zohren F, Schroeder T, et al
    Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Arch Neurol. 2011;68:1428-31.
    PubMed     Text format     Abstract available
    
    
    
39. KIM SH , Kim W, Li XF, Jung IJ, et al
    Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Arch Neurol. 2011;68:1412-20.
    PubMed     Text format     Abstract available
    
    
    October 2011
40. KINKEL RP , Dontchev M, Kollman C, Skaramagas TT, et al
    Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes: A 10-Year Follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Ne
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    September 2011
41. QIAN P , Cross AH, Naismith RT
    Lack of response to monoclonal antibody therapy in neuromyelitis optica.
    Arch Neurol. 2011;68:1207-9.
    PubMed     Text format    
    
    
    August 2011
42. MARDER E , Gupta P, Greenberg BM, Frohman EM, et al
    No Cerebral or Cervical Venous Insufficiency in US Veterans With Multiple Sclerosis.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
43. VAKNIN-DEMBINSKY A , Abramsky O, Petrou P, Ben-Hur T, et al
    Myasthenia Gravis-Associated Neuromyelitis Optica-Like Disease: An Immunological Link Between the Central Nervous System and Muscle?
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
44. KITLEY JL , Leite MI, Matthews LA, Palace J, et al
    Use of mitoxantrone in neuromyelitis optica.
    Arch Neurol. 2011;68:1086.
    PubMed     Text format    
    
    
    July 2011
45. BAGERT BA , Marder E, Stuve O
    Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
46. KARACOSTAS D , Hadjigeorgiou G, Ioannidis P, Milonas I, et al
    How safe could intrathecal transplantation of mesenchymal stem cells be considered in multiple sclerosis?
    Arch Neurol. 2011;68:955.
    PubMed     Text format    
    
    
    
47. COLLONGUES N , Cabre P, Marignier R, Zephir H, et al
    A benign form of neuromyelitis optica: does it exist?
    Arch Neurol. 2011;68:918-24.
    PubMed     Text format     Abstract available
    
    
    
48. UZAWA A , Mori M, Masuda S, Kuwabara S, et al
    Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica.
    Arch Neurol. 2011;68:913-7.
    PubMed     Text format     Abstract available
    
    
    
49. MATIELLO M , Pittock SJ, Porrata L, Weinshenker BG, et al
    Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica.
    Arch Neurol. 2011;68:953-5.
    PubMed     Text format    
    
    
    June 2011
50. FAREZ MF , Correale J
    Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    April 2011
51. BUNYAN RF , Popescu BF, Carter JL, Caselli RJ, et al
    Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination.
    Arch Neurol. 2011;68:525-8.
    PubMed     Text format     Abstract available
    
    
    
52. BUCK D , Cepok S, Hoffmann S, Grummel V, et al
    Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis.
    Arch Neurol. 2011;68:480-7.
    PubMed     Text format     Abstract available
    
    
    
53. RAMAGOPALAN SV , Meier UC, Conacher M, Ebers GC, et al
    Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis.
    Arch Neurol. 2011;68:469-72.
    PubMed     Text format     Abstract available
    
    
    
54. CREE BA , Stuart WH, Tornatore CS, Jeffery DR, et al
    Efficacy of Natalizumab Therapy in Patients of African Descent With Relapsing Multiple Sclerosis: Analysis of AFFIRM and SENTINEL Data.
    Arch Neurol. 2011;68:464-8.
    PubMed     Text format     Abstract available
    
    
    
55. COYLE PK
    Pediatric multiple sclerosis: just like their elders?
    Arch Neurol. 2011;68:419-21.
    PubMed     Text format    
    
    
    
56. ALMEKHLAFI MA , Clark AW, Lucchinetti CF, Zhang Y, et al
    Neuromyelitis optica with extensive active brain involvement: an autopsy study.
    Arch Neurol. 2011;68:508-12.
    PubMed     Text format     Abstract available
    
    
    
57. KIM SH , Kim W, Park MS, Sohn EH, et al
    Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
    Arch Neurol. 2011;68:473-9.
    PubMed     Text format     Abstract available
    
    
    February 2011
58. JONES DT , Mateen FJ, Lucchinetti CF, Jack CR Jr, et al
    Default mode network disruption secondary to a lesion in the anterior thalamus.
    Arch Neurol. 2011;68:242-7.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: